ValiRx Plc
("ValiRx" or the "Company")
Issue of Equity
ValiRx announces that, on 13 August 2010, the Company issued 7,407,333 new ordinary shares of 0.1p each ("Ordinary Shares") to Cancer Research Technology Limited ("CRT") at an issue price of 0.45p per share, being the mid-market price of the Ordinary Shares on 13 August 2010. The share issue was in respect of the payment of milestones and other payments due to CRT according to the terms and conditions of the option agreement entered into in 2008 with CRT and the subsequent licensing agreement with CRT signed on 11 August 2010.
Application has been made for the new Ordinary Shares to be admitted to trading on AIM and dealings are expected to commence on 19 August 2010. Following the issue of the new Ordinary Shares, the total number of Ordinary Shares now in issue is 343,923,790.
For further information, please contact:
ValiRx plc |
|
Dr. Satu Vainikka |
Tel: +44 (0) 20 3008 4416 |
|
|
|
|
WH Ireland Limited - Nominated Adviser |
|
Robin Gwyn |
Tel: +44 (0) 161 832 2174 |
|
|
Hybridan LLP - Broker |
|
Claire Noyce |
Tel: +44 (0) 207 947 4350 |
|
|
Peckwater PR |
|
Tarquin Edwards |
Tel: +44 (0)7879 458 364 |
|